amyotrophic lateral sclerosis

(redirected from Riluzole)
Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.

a·my·o·tro·phic lateral sclerosis

 (ā′mī-ə-trō′fĭk, -trŏf′ĭk, ā-mī′-)
n. Abbr. ALS
A chronic, progressive disease marked by gradual degeneration of the nerve cells in the spinal cord that control voluntary muscle movement, causing muscle weakness, atrophy, and eventual paralysis. Also called Lou Gehrig's disease.

amyotrophic lateral sclerosis

(ˌæmɪəʊˈtrəʊfɪk)
n
(Pathology) a form of motor neurone disease in which degeneration of motor tracts in the spinal cord causes progressive muscular paralysis starting in the limbs. Also called: Lou Gehrig's disease

a•my•o•troph′ic lat′eral sclero′sis

(ˌeɪ maɪ əˈtrɒf ɪk, -ˈtroʊ fɪk, eɪˌmaɪ ə-)
n.
a nervous system disease in which degeneration of motor neurons in the brain stem and spinal cord leads to atrophy and paralysis of the voluntary muscles. Abbr.: ALS Also called Lou Gehrig's disease.
[1885–90; a-6 + myo- + -trophic]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.amyotrophic lateral sclerosis - thickening of tissue in the motor tracts of the lateral columns and anterior horns of the spinal cordamyotrophic lateral sclerosis - thickening of tissue in the motor tracts of the lateral columns and anterior horns of the spinal cord; results in progressive muscle atrophy that starts in the limbs
nervous disorder, neurological disease, neurological disorder - a disorder of the nervous system
induration, sclerosis - any pathological hardening or thickening of tissue
References in periodicals archive ?
M2 EQUITYBITES-February 1, 2018-Aquestive Therapeutics passes US FDA's orphan drug designation for Riluzole Oral Soluble Film for ALS
M2 PHARMA-February 1, 2018-Aquestive Therapeutics passes US FDA's orphan drug designation for Riluzole Oral Soluble Film for ALS
The presentation entitled "Ibudilast - Phosphodiesterase Type 4 Inhibitor - Bi-Modal Therapy with Riluzole in Early Cohort and Advanced Amyotrophic Lateral Sclerosis Patients - Single-Center Adaptive Design Six-Month Double-Blind - Placebo-Controlled Phase 1b/2a Epoch Followed by Six-Month Open Label Extension Epoch, Washout and Post-Washout Epoch - Final Report and Future Directions" will be available for review throughout the afternoon on April 27th.
Contract award notice: Framework agreement for the supply of human immunoglobulin antihepatitis b (doe), Riluzole (doe) tablet, Levobupivacaine (doe), Linezolid (doe) oral suspension and parenteral pantoprazole (doe)
sup][4] Although riluzole and edaravone (RADICAVA) have been shown to slow the disease progression and have a modest improvement in survival by several months,[sup][5] currently, ALS is still lack of effective cures.
To date, there is no cure for the disease, although two FDA-approved medications, riluzole (Rilutek) and edaravone (Radicava), can slow its progression.
There currently are two FDA-approved drugs, riluzole (Rilutek) and edaravone (Radicava), that slow progression of the disease, while physical therapy can help strengthen unaffected muscles.
The only other approved treatment specifically for ALS, riluzole, was approved in 1995 and modestly slows the disease progression in some patients.
8) Riluzole and memantine reduce GLU activity and both are FDA-approved for treating neurodegenerative disorders, such as ALS and AD, respectively.
Despite more than 30 clinical trials since 1995, only one ALS treatment has been brought to market, and that compound, Riluzole, extends survival by only two to three months.
The drug's developers believe that the use of Riluzole in the early stages of AD might prevent or at least retard disease progression that leads to widespread irreversible neuronal loss and significant cognitive dysfunction.